## COVID-19 Clinical effort 

Current worldwide research clinical efforts against COVID-19. Drug candidates suggested from these studies are provided here and updated daily. We also include our initial data anlaysis results from previous antiviral drug discovery studies to facilitate such efforts. We seek experts' opinions and efforts to further validate these candidates, which will be continuously re-defined and selected based on their prior data on COVID-19 related viruses and newly generated data on COVID-19.

### COVID-19 Clinical Trials registration list

A list of registered clinical trials for COVID-19 infection is collected in the table below. This data was initially collected from [Biocentury](https://www.biocentury.com/article/304368) and sorted based on registration date. Additionally, [dimensions.ai](https://covid-19.dimensions.ai/) provides a full list of clinical trials regarding COVID-19. We will continue to provide updated clinical trial information involving potential drug candidates.

| Registration number                                          | Intervention                                                 | Type                      | Registration date |
| ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------- | ----------------- |
| [ChiCTR2000029308](http://www.chictr.org.cn/showprojen.aspx?proj=48684) | Lopinavir/ritonavir; interferon α 2b                         | Antiviral                 | 2020/1/23         |
| [ChiCTR2000029386](http://www.chictr.org.cn/showprojen.aspx?proj=http://www.chictr.org.cn/showprojen.aspx?proj=48777) | Lopinavir/ritonavir; methylprednisolone; interferon α        | Antiviral; Corticosteroid | 2020/1/28         |
| [ChiCTR2000029387](http://www.chictr.org.cn/showprojen.aspx?proj=48782) | Lopinavir/ritonavir; ribavirin; interferon α-1b              | Antiviral                 | 2020/1/28         |
| [NCT04244591](https://clinicaltrials.gov/ct2/show/NCT04244591) | Methylprednisolone                                           | Corticosteroid            | 2020/1/28         |
| [ChiCTR2000029468](http://www.chictr.org.cn/showprojen.aspx?proj=48919) | Lopinavir/ritonavir; emtricitabine/tenofovir alafenamide fumarate | Antiviral                 | 2020/2/2          |
| [ChiCTR2000029496](http://www.chictr.org.cn/showprojen.aspx?proj=48809) | Lopinavir/ritonavir; Novaferon                               | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029539](http://www.chictr.org.cn/showprojen.aspx?proj=48991) | Lopinavir/ritonavir                                          | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029541](http://www.chictr.org.cn/showprojen.aspx?proj=48992) | Darunavir/cobicistat; Lopinavir/ritonavir; thymosin          | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029542](http://www.chictr.org.cn/showprojen.aspx?proj=48968) | Chloroquine                                                  | Antiviral                 | 2020/2/3          |
| [ChiCTR2000029548](http://www.chictr.org.cn/showprojen.aspx?proj=49015) | Baloxavir Marboxil; Favipiravir; Lopinavir/ritonavir         | Antiviral                 | 2020/2/4          |
| [NCT04252885](https://clinicaltrials.gov/ct2/show/NCT04252885) | Umifenovir (Arbidol)                                         | Antiviral                 | 2020/2/5          |
| [NCT04255017](https://clinicaltrials.gov/ct2/show/NCT04255017) | Umifenovir (Arbidol); Oseltamivir; Lopinavir/ritonavir       | Antiviral                 | 2020/2/5          |
| [NCT04257656](https://clinicaltrials.gov/ct2/show/NCT04257656) | Remdesivir                                                   | Antiviral                 | 2020/2/6          |
| [ChiCTR200029600](http://www.chictr.org.cn/showprojen.aspx?proj=49042) | Favipiravir, Lopinavir/Ritonavir + alpha-Interferon          | Antiviral                 | 2020/2/6          |
| [ChiCTR2000029853](http://www.chictr.org.cn/showprojen.aspx?proj=49532) | Azvudine                                                     | Antiviral                 | 2020/2/16         |
| [NCT04273529](https://clinicaltrials.gov/ct2/show/NCT04273529) | Thalidomide                                                  | Immunomodulatory agent    | 2020/2/18         |
| [ChiCTR2000030000](http://www.chictr.org.cn/showprojen.aspx?proj=49748) | Ganovo (Danoprevir)/ritonavir; Peginterferon alfa-2a         | Antiviral                 | 2020/2/19         |
| [NCT04280588](https://clinicaltrials.gov/ct2/show/NCT04280588) | Fingolimod                                                   | Receptor modulator        | 2020/2/21         |
| [ChiCTR2000030055](http://www.chictr.org.cn/showprojen.aspx?proj=49864) | Dipyridamole                                                 | Inhibitor                 | 2020/2/22         |


### COVID-19 related projects around the world
The PDF document below published by [mybiogate](http://mybiogate.com) lists a collection of projects related to COVID-19.  This table organizes the projects as: therapeutics, vaccines, diagnostic tools, and medical devices. Additionally, each project's organization, brief introduction, research or clinical progress, location, and other potential indications are listed. In total, there are 55 therapeutic, 17 vaccine, 14 diagnostic, and 16 medical device projects listed on this table.

[Download PDF](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/file_quanqiuzhongwenxiangmu.pdf)

---

## Detailed Drug information of current published or ongoing in vitro or clinical studies on COVID-19

The information below is collected from recent research articles, news articles, or clinical reports of COVID-19 studies contributed from various research groups worldwide. The source links or full article download are provided to facilitate your own investigation and research on these molecules. 


| Drug Name             | Structure                                                    | MoA                                                 | Indication                                                   | DrugBank URL                                                 | Anti-2019nCoV Evidence                          | Reference                                                    |
| --------------------- | ------------------------------------------------------------ | --------------------------------------------------- | ------------------------------------------------------------ | ------------------------------------------------------------ | ----------------------------------------------- | ------------------------------------------------------------ |
| Remdesivir            | ![img3](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_remdesivir.png) | RNA  polymerase inhibitor                           | Anti-Ebola passed Phase III, nCoV Phase III                  | [DB14761](https://www.drugbank.ca/drugs/DB14761)             | In Vitro Assay, Clinical report, Clinical trial | [7](http://www.xinhuanet.com/english/2020-01/30/c_138742163.htm); [8](https://www.nejm.org/doi/10.1056/NEJMoa2001191); [14](http://clarivate.com.cn/coronavirus-resources/images/Remdesivir.pdf); [15](https://www.nature.com/articles/s41422-020-0282-0); [16](https://clinicaltrials.gov/ct2/show/NCT04257656) |
| Lopinavir             | ![img1](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_lopinavir.png) | Protease inhibitor                                  | Anti-HIV approved                                            | [DB01601](https://www.drugbank.ca/drugs/DB01601)             | Clinical trial                                  | [1](http://www.chictr.org.cn/showprojen.aspx?proj=48684); [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919); [3](http://www.chictr.org.cn/showprojen.aspx?proj=48809); [4](http://www.chictr.org.cn/showprojen.aspx?proj=48991); [5](http://www.chictr.org.cn/showprojen.aspx?proj=48782); [6](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml) |
| Ritonavir             | ![img2](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ritonavir.png) | Protease inhibitor                                  | Anti-HIV approved                                            | [DB00503](https://www.drugbank.ca/drugs/DB00503)             | Clinical trial                                  | [1](http://www.chictr.org.cn/showprojen.aspx?proj=48684); [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919); [3](http://www.chictr.org.cn/showprojen.aspx?proj=48809); [4](http://www.chictr.org.cn/showprojen.aspx?proj=48991); [5](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml); [6](http://www.chictr.org.cn/showprojen.aspx?proj=48782) |
| Emtricitabine         | ![img13](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_emtricitabine.png) | nucleoside reverse  transcriptase inhibitor         | Anti-HIV  approved, anti-HBV                                 | [DB00879](https://www.drugbank.ca/drugs/DB00879)             | Clinical trial                                  | [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919)     |
| Tenofovir             | ![img14](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_tenofovir.png) | nucleoside reverse  transcriptase inhibitor         | Anti-HIV Phase III, anti-HBV                                 | [DB14126](https://www.drugbank.ca/drugs/DB14126)             | Clinical trial                                  | [2](http://www.chictr.org.cn/showprojen.aspx?proj=48919)     |
| Ribavirin             | ![img12](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_ribavirin.png) | viral mRNA and  protein synthesis inhibitor         | Anti-HCV,  Anti-HBV, Anti-SARS, Anti-influenza, etc          | [DB00811](https://www.drugbank.ca/drugs/DB00811)             | Clinical trial                                  | [5](http://www.chictr.org.cn/showprojen.aspx?proj=48782)     |
| Umifenovir            | ![img5](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_arbidol.png) |                                                     | Influenza approved, nCoV Phase 4                             | [DB13609](https://www.drugbank.ca/drugs/DB13609)             | Clinical trial                                  | [9](https://clinicaltrials.gov/ct2/show/NCT04252885); [22](https://clinicaltrials.gov/ct2/show/NCT04255017) |
| Favipiravir           | ![img6](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_favipiravir.png) | RNA polymerase inhibitor                            | Anti-influenza approved, anti-Ebola Phase II                 | [DB12466](https://www.drugbank.ca/drugs/DB12466)             | Clinical trial                                  | [10](http://www.xinhuanet.com/english/2020-02/01/c_138747115.htm); [18](http://www.chictr.org.cn/showprojen.aspx?proj=49042) |
| Darunavir             | ![img10](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_darunavir.png) | Protease inhibitor                                  | Anti-HIV approved                                            | [DB01264](https://www.drugbank.ca/drugs/DB01264)             | Clinical trial                                  | [11](http://www.chictr.org.cn/showprojen.aspx?proj=48992)    |
| Cobicistat            | ![img11](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_cobicistat.png) |                                                     | Anti-HIV approved                                            | [DB09065](https://www.drugbank.ca/drugs/DB09065)             | Clinical trial                                  | [11](http://www.chictr.org.cn/showprojen.aspx?proj=48992)    |
| Methylprednisolone    | ![img9](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_methylprednisolone.png) | Corticosteroid                                      | nCoV Phase II, allergic asthma and rheumatic disorders approved | [DB00959](https://www.drugbank.ca/drugs/DB00959)             | Clinical trial                                  | [12](http://www.chictr.org.cn/showprojen.aspx?proj=48777); [13](https://clinicaltrials.gov/ct2/show/NCT04244591) |
| Baloxavir marboxil    | ![img14](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_baloxavirmarboxil.png) | Polymerase inhibitor                                | anti-influenza approved                                      | [DB13997](https://www.drugbank.ca/drugs/DB13997)             | Clinical trial                                  | [21](http://www.chictr.org.cn/showprojen.aspx?proj=49015)    |
| Oseltamivir           | ![img15](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_oseltamivir.png) | Neuraminidase inhibitor; Sialidase inhibitor        | anti-influenza approved, nCoV Phase III                      | [DB00198](https://www.drugbank.ca/drugs/DB00198)             | Clinical trial                                  | [22](https://clinicaltrials.gov/ct2/show/NCT04255017)        |
| IFN alpha-1b          |                                                              | Immunomodulation                                    | Interferon                                                   |                                                              | Clinical trial                                  | [5](http://www.chictr.org.cn/showproj.aspx?proj=48782); [6](http://www.nhc.gov.cn/yzygj/s7652m/202001/7450028ab6084101ae8110f0aaf81271.shtml) |
| Danoprevir            | ![img17](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_danoprevir.png) | Protease inhibitor                                  | anti-HCV Phase III, nCoV Phase 4                             | [DB11779](https://www.drugbank.ca/drugs/DB11779)             | Clinical trial                                  | [23](http://www.chictr.org.cn/showprojen.aspx?proj=49748)    |
| Peginterferon alfa-2a |                                                              | Immunomodulation                                    | HCV approved, nCoV Phase 4                                   | [DB00008](https://www.drugbank.ca/drugs/DB00008)             | Clinical trial                                  | [23](http://www.chictr.org.cn/showprojen.aspx?proj=49748)    |
| Chloroquine           | ![img4](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_chloroquine.png) |                                                     | Antimalarial approved, anti-HIV phase III, anti-HCV, nCoV Phase  4 | [DB14761](https://www.drugbank.ca/drugs/DB14761)             | In Vitro Assay, Clinical trial                  | [7](http://www.xinhuanet.com/english/2020-01/30/c_138742163.htm); [15](https://www.nature.com/articles/s41422-020-0282-0); [17](http://www.chictr.org.cn/showprojen.aspx?proj=48968) |
| Azvudine              | ![img4](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_azuvudine.png) |                                                     | anti-HIV approved                                            | [PubChem 24769759](https://pubchem.ncbi.nlm.nih.gov/compound/Azvudine) | Clinical trial                                  | [19](http://www.chictr.org.cn/showproj.aspx?proj=49532); [20](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140803/) |
| Dipyridamole          | ![img20](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_dipyridamole.png) | Adenosine deaminase and phosphodiesterase inhibitor | nCoV Phase 4; Phase 4 completed for stroke prevention; Phase 4 completed for coronary arteriosclerosis | [DB00975](https://www.drugbank.ca/drugs/DB00975)             | Clinical Trial                                  | [24](http://www.chictr.org.cn/showprojen.aspx?proj=49864); [25](https://www.medrxiv.org/content/10.1101/2020.02.27.20027557v1.full.pdf) |
| Thalidomide           | ![img23](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_thalidomide.png) |                                                     | nCoV Phase 2;  Phase 3 completed for cancers                 | [DB01041](https://www.drugbank.ca/drugs/DB01041)             | Clinical Trial                                  | [26](https://clinicaltrials.gov/ct2/show/NCT04273529)        |
| Fingolimod            | ![img24](http://ghddiai.oss-cn-zhangjiakou.aliyuncs.com/file/structure_fingolimod.png) |                                                     | nCoV Phase 2; Phase 4 completed for Multiple Sclerosis       | [DB08868](https://www.drugbank.ca/drugs/DB08868)             | Clinical Trial                                  | [27](https://clinicaltrials.gov/ct2/show/NCT04280588)        |



---

<br>

<br>

<br>

Your [**feedback**](https://github.com/GHDDI-AILab/Targeting2019-nCoV/issues) is highly appreciated.
